Verrucous form of chilblain lupus erythematosus.
A 45-year-old woman had symmetrical livid plaques with yellowish hyperkeratoses for 5 years, which progressed on to the fingers and toes and on the soles of the feet. Two years later creamy, whitish areas and maceration appeared on the buccal mucosa and the lips. A skin biopsy revealed massive collagen hyaline degeneration in the perivascular area, hyperkeratosis and hypergranulosis, small lymphocyte infiltrates with several melanophages and extravasates of erythrocytes in the upper corium in perivascular areas and hydropic degeneration of basal keratinocytes. The findings using direct immunofluorescence were compatible with lupus erythematosus (LE). Laboratory investigation showed a slight leucopenia and thrombopenia, a slightly elevated erythrocyte sedimentation rate, hypocomplementaemia C3 and C4, a high titre of rheumatoid factor and antinuclear antibodies positivity of extractable nuclear antigen. The results reflected probably the development of a systemic form of the disease. The patient was successfully managed by methylprednisolone and hydroxychloroquine. After 1 year of therapy, a new skin biopsy revealed a substantial reduction of hyperkeratosis and hyaline degeneration of collagen tissue in the perivascular areas. The combination of the extensive hyperkeratosis and hyalinization thus seems to be features of the long-lasting, untreated lesions in chilblain LE.
Pock
L
L
Dermatohistopathological laboratory, Prague, Czech Republic. lumir.pock@atlas.cz
Petrovská
P
P
Becvár
R
R
Mandys
V
V
Hercogová
J
J
D001707:Biopsy, Needle; D002647:Chilblains / Q000209:etiology* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D005533:Foot Dermatoses / Q000473:pathology; D006229:Hand Dermatoses / Q000473:pathology; D006801:Humans; D006886:Hydroxychloroquine / Q000008:administration & dosage; D007642:Keratosis / Q000473:pathology; D008178:Lupus Erythematosus, Cutaneous / Q000150:complications* / Q000188:drug therapy / Q000473:pathology*; D008775:Methylprednisolone / Q000008:administration & dosage; D008875:Middle Aged; D009061:Mouth Mucosa / Q000473:pathology*; D018570:Risk Assessment; D016896:Treatment Outcome
D006886:Hydroxychloroquine; D008775:Methylprednisolone